HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTSPRNewsWire • 05/06/25
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)PRNewsWire • 04/28/25
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda FormulationPRNewsWire • 04/24/25
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile MarketInvestors Business Daily • 04/11/25
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating PolyneuropathyPRNewsWire • 04/10/25
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant EligibilityPRNewsWire • 04/09/25
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung CancerPRNewsWire • 04/07/25
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor IndicationsPRNewsWire • 03/31/25
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?Zacks Investment Research • 03/21/25
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In RevenueInvestors Business Daily • 03/13/25
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/18/25
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top EstimatesZacks Investment Research • 02/18/25
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPSPRNewsWire • 02/18/25
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating ResultsPRNewsWire • 02/04/25